Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05309616
PHASE2

Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis

Sponsor: Yale University

View on ClinicalTrials.gov

Summary

The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.

Official title: Effects of IL-17A Inhibition on Idiopathic Subglottic Stenosis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2025-02-20

Completion Date

2026-05

Last Updated

2026-01-27

Healthy Volunteers

No

Interventions

DRUG

Taltz

Participants will receive160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2,4,6,8,10,12 and then 80 mg every 4 weeks

Locations (1)

Yale New Haven Hospital

New Haven, Connecticut, United States